Compare Las Vegas Sands Corp. (LVS) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs McKesson Corporation — how do they compare? Las Vegas Sands Corp. trades at $36.38 (market cap $23.38B), while McKesson Corporation trades at $930.2 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 4.6× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and McKesson Corporation for 74 Days on average.
| LVS | MCK | |
|---|---|---|
Market Cap | $23.38B | $108.46B |
Volume | 6,994,661 | 712,607 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $995.69 |
52-Week Low | $35.81 | $725.17 |
Typical Hold Time | 72 Days | 74 Days |
Enterprise Value | $35.27B | $115.00B |
Dividend Yield | 3.32% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $35.81, down 1.38% today, with a bearish technical signal despite bullish oscillators. The company shows strong fundamentals with 2025 revenue of $13.02B and net income of $1.63B, supported by consistent earnings beats in recent quarters. Analyst consensus remains strongly bullish with 59% buy ratings and a $59.78 price target, representing 67% upside potential from current levels.
LVS presents compelling value with attractive valuation multiples (P/E 13.99, EV/EBITDA 7.64) and robust profitability (ROE 134.29%). Key risks include high debt levels (debt-to-asset ratio 73.15%) and sensitivity to Macao gaming regulations. The stock's current discount to analyst targets offers significant upside if operational momentum continues.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
